Amgen ((AMGN) is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending a clear message: institutions are leaning in. When a mega-cap healthcare name breaks out while the broader market debates growth versus defensives, investors should pay attention. The numbers tell a compelling story.At yesterday afternoon’s earnings report, Amgen reported solid growth in the fourth quarter and full year 2025, with total revenues rising ro ...

Core Viewpoint - Amgen Inc. is experiencing strong performance and positive analyst outlook despite facing some challenges, with a maintained "Buy" rating and an increased price target from Cowen & Co. [1][5] Financial Performance - Amgen's fourth-quarter performance in 2025 exceeded expectations for both revenue and earnings per share, supporting a positive outlook from analysts [2][5] - The stock price is currently $338.59, reflecting a 1.80% decrease or $6.20 drop, with a market capitalization of approximately $182.32 billion [4] Growth Prospects - Key products like Repatha and Uplizna are expected to drive future growth, offsetting losses from Prolia and Xgeva [2][5] - Despite regulatory uncertainties and pipeline attrition, Amgen's long-term prospects remain strong, bolstered by positive data from Repatha and progress with MariTide [3][5] Market Activity - The stock has fluctuated between $338.59 and $349.50 today, with a yearly high of $353.25 and a low of $261.43 [4]

U.S. stocks were mixed, with the Dow Jones index gaining more than 250 points on Wednesday.Shares of Cirrus Logic, Inc. (NASDAQ:CRUS) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter financial results and issued fourth-quarter sales guidance above estimates.Cirrus Logic reported quarterly earnings of $2.97 per share which beat the analyst consensus estimate of $2.44 per share. The company reported quarterly sales of $580.620 million which beat the analyst ...

Key Takeaways AMGN beat Q4 EPS and sales estimates as total revenues rose 9% on strong global demand across key brands.Amgen saw robust growth from Repatha, Evenity and Tezspire, offsetting pricing pressure and higher costs.AMGN is advancing MariTide with six phase III obesity studies, targeting monthly dosing via autoinjector.Amgen (AMGN) reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of $4.76 per share. Earnings were relatively flat year over yea ...

Group 1 - Amgen reported strong Q4 2025 results and provided full-year 2026 guidance that exceeded Street expectations [2] - The company is effectively managing losses of exclusivity on several large products [2] Group 2 - The Growth Stock Forum focuses on identifying attractive risk/reward situations in growth and biotech stocks [2]

Core Insights - Ligand Pharmaceuticals will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, with CEO Todd Davis and CFO Tavo Espinoza attending a fireside chat [1] - The company will also host one-on-one meetings with investors during the conference, encouraging interested parties to contact their Oppenheimer representative for arrangements [2] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company focused on supporting the clinical development of high-value medicines through financing and licensing technologies [3] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [3] - Ligand's strategy includes funding mid- to late-stage drug development programs in exchange for economic rights, purchasing royalty rights, and licensing technology to assist partners in drug discovery and development [3] - The company operates two royalty-generating technology platforms: Captisol®, which enhances drug solubility and stability, and NITRICIL™, which allows for tunable dosing and adjustable drug release profiles [3] - Ligand has established partnerships with leading pharmaceutical companies such as Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

For the quarter ended December 2025, Amgen (AMGN) reported revenue of $9.87 billion, up 8.6% over the same period last year. EPS came in at $5.29, compared to $5.31 in the year-ago quarter.The reported revenue represents a surprise of +4.23% over the Zacks Consensus Estimate of $9.47 billion. With the consensus EPS estimate being $4.76, the EPS surprise was +11.18%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their nex ...

Amgen (AMGN) came out with quarterly earnings of $5.29 per share, beating the Zacks Consensus Estimate of $4.76 per share. This compares to earnings of $5.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +11.18%. A quarter ago, it was expected that this world's largest biotech drugmaker would post earnings of $5 per share when it actually produced earnings of $5.64, delivering a surprise of +12.8%.Over the last four quarters ...

Amgen (NasdaqGS:AMGN) Q4 2025 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsCasey Capparelli - VP of Investor RelationsDavid Amsellem - Managing DirectorJames Bradner - EVP of Research and DevelopmentMurdo Gordon - EVP of Global Commercial OperationsPeter Griffith - CFORobert Bradway - CEOTerence Flynn - Managing DirectorUmer Raffat - Managing DirectorYaron Werber - Managing DirectorConference Call ParticipantsAlex Hammond - AnalystChris Schott - AnalystCourtney Breen - Senior Research Ana ...